http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022226344-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e9010f8ae7c32e8b62cd768952bf535 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-554 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554 |
| filingDate | 2022-01-07^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe4a773602860b871433bf563f8e9986 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fa58218981c3ac94b258f2b1133192d |
| publicationDate | 2022-07-21^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022226344-A1 |
| titleOfInvention | Crystalline forms of a ryanodine receptor modulator and uses thereof |
| abstract | The present disclosure relates to crystalline forms of the compound 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, pharmaceutical compositions comprising these compounds and uses thereof to treat diseases and conditions associated with Ryanodine Receptor (RyR) dysfunction, in particular cardiac and musculoskeletal disorders and diseases. |
| priorityDate | 2021-01-08^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 445 of 445.